Shorter Proton Therapy With MRI Guidance for Localized Prostate Cancer
Tests a 2-session proton radiation treatment in men with localized prostate cancer.
Plain-language title generated from the registry record
Registry title: Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
Key facts
- Where
- Hong Kong, Hong KongSee the site
Where in Hong Kong
- Hong Kong Sanatorium and HospitalHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hong Kong Sanatorium & Hospital
- Trial code
- NCT07130682
- Record updated
- 16 March 2026
- Original description
This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation. However, it is expensive and not easily accessible for many patients. To make it more affordable and accessible, this study is testing whether 2 fractions of stereotactic body proton therapy (SBPT) can be as safe and effective as the standard 5 sessions.Read full original descriptionShow less
2-fraction Stereotactic Body Proton Therapy (SBPT) With Magnetic Resonance Imaging (MRI) Guidance in Localized Prostate Cancer: A Single-arm Phase II Non-randomized Trial
This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation. However, it is expensive and not easily accessible for many patients. To make it more affordable and accessible, this study is testing whether 2 fractions of stereotactic body proton therapy (SBPT) can be as safe and effective as the standard 5 sessions.
Inclusion: Men aged < 18 years with histologically confirmed low- or intermediate-risk prostate cancer per NCCN guidelines; Eastern Cooperative Oncology Group (ECOG) performance status <2; Ability to undergo magnetic resonance imaging (MRI) simulation scans without absolute contraindications, such as cardiac implantable electronic devices; Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.
Exclusion: Prior pelvic radiotherapy, chemotherapy, radical prostatectomy, cryosurgery, or focal therapy (e.g. high-intensity focused ultrasound [HIFU]) for prostate cancer; Transurethral resection of the prostate (TURP) < 8 weeks prior to SBPT; Previous androgen deprivation therapy (ADT) lasting more than 6 months; History of inflammatory bowel disease or other cancers (except prostate cancer); History of bladder neck or urethral stricture; Prostate volume > 100cc on MRI; Unilateral or bilateral hip replacements; Nodal or distant metastases, as indicated by computed tomography (CT), MRI, or prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans.